Close Menu

NEW YORK — Women's health diagnostic firm Progenity on Thursday announced a 70 percent drop in second quarter revenues, its first financial results since going public earlier this year.

For the three-month period ended June 30, Progenity reported $17.3 million in revenue, down from $57.2 million in the year-ago quarter. Second quarter revenues were impacted by "a $10.3 million accrual for refunds to government payors," the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.